First-in-human results: ¹⁷⁷Lu-FAP-2286 PTRT, applied in a broad spectrum of cancers, was relatively well tolerated, with acceptable side effects, and demonstrated long retention of the radiopeptide. ow.ly/xZKK50I8nQS #MedicalResearch #NucMed #Cancer

18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study | Journal of Nuclear Medicine jnm.snmjournals.org/content/early/…

Current Issue: 18F-FDG and 68GA–Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence dlvr.it/ST6L74

PET evaluation of changes in c-MET expression in metastatic #RenalCellCarcinoma under therapy with cabozantinib. Presentation by LenaUnterrainer UCLA. #SNMMI23 written coverage by Rashid K. Sayyid University of Toronto > bit.ly/3r5jsSh SNMMI

LenaUnterrainer in front of thousands #EANM23 identifying dark horses of theranostics... Could CA-IX be the next game changing theranostic? Ken Herrmann

Breakthrough results from #PSMAfore at #ESMO23: #PLUVICTO Lu177-PSMA617 therapy rPFS = 12 months vs change of AR-inhibitors rPFS = 5.6 months in patients with mCRPC before chemotherapy ! Double !! #theranostics #PSMA Novartis SNMMI oncologypipeline.com/apexonco/esmo-…

Low- and high-volume disease in metastatic hormone-sensitive #ProstateCancer: From #CHAARTED to PSMA PET. Presentation by LenaUnterrainer UCLA. #ESMO23 written coverage by Rashid K. Sayyid University of Toronto > bit.ly/46WIGSq ESMO - Eur. Oncology

Low- and high-volume disease in #mHSPC, from #CHAARTED to PSMA-PET: An international multicenter retrospective study. Presentation by LenaUnterrainer UCLA. #GU24 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3Ufz9Th ASCO